First Time Loading...

Celltrion Inc
KRX:068270

Watchlist Manager
Celltrion Inc Logo
Celltrion Inc
KRX:068270
Watchlist
Price: 183 400 KRW 0.44% Market Closed
Updated: Jun 17, 2024
Have any thoughts about
Celltrion Inc?
Write Note

Intrinsic Value

Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. [ Read More ]

The intrinsic value of one Celltrion Inc stock under the Base Case scenario is 154 988.39 KRW. Compared to the current market price of 183 400 KRW, Celltrion Inc is Overvalued by 15%.

Key Points:
Intrinsic Value
Base Case
154 988.39 KRW
Overvaluation 15%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Celltrion Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling Celltrion Inc stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Celltrion Inc

Current Assets 5T
Cash & Short-Term Investments 731.8B
Receivables 975.7B
Other Current Assets 3.3T
Non-Current Assets 14.9T
Long-Term Investments 135.4B
PP&E 1.2T
Intangibles 13.3T
Other Non-Current Assets 222.1B
Current Liabilities 2.5T
Accounts Payable 50.9B
Accrued Liabilities 205.7B
Short-Term Debt 1.6T
Other Current Liabilities 606.4B
Non-Current Liabilities 466.3B
Long-Term Debt 107.1B
Other Non-Current Liabilities 359.2B
Efficiency

Earnings Waterfall
Celltrion Inc

Revenue
2.3T KRW
Cost of Revenue
-1.2T KRW
Gross Profit
1.1T KRW
Operating Expenses
-615.1B KRW
Operating Income
479.3B KRW
Other Expenses
-86.5B KRW
Net Income
392.8B KRW

Free Cash Flow Analysis
Celltrion Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Celltrion Inc's profitability score is 56/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Operating Income
Exceptional Revenue Growth Forecast
Positive Net Income
56/100
Profitability
Score

Celltrion Inc's profitability score is 56/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Celltrion Inc's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Low D/E
Short-Term Solvency
71/100
Solvency
Score

Celltrion Inc's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Celltrion Inc

Wall Street analysts forecast Celltrion Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Celltrion Inc is 247 310.77 KRW with a low forecast of 173 720 KRW and a high forecast of 315 000 KRW.

Lowest
Price Target
173 720 KRW
5% Downside
Average
Price Target
247 310.77 KRW
35% Upside
Highest
Price Target
315 000 KRW
72% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

Price
Celltrion Inc

1M 1M
-4%
6M 6M
+3%
1Y 1Y
+13%
3Y 3Y
-27%
5Y 5Y
+2%
10Y 10Y
+423%
Annual Price Range
183 400
52w Low
131 800
52w High
231 500
Price Metrics
Average Annual Return 7.9%
Standard Deviation of Annual Returns 61.06%
Max Drawdown -64%
Shares Statistics
Market Capitalization 38T KRW
Shares Outstanding 218 050 000
Percentage of Shares Shorted
N/A

Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Celltrion Inc Logo
Celltrion Inc

Country

Korea

Industry

Biotechnology

Market Cap

38T KRW

Dividend Yield

0.27%

Description

Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. The company is headquartered in Incheon, Incheon. The company went IPO on 2005-07-19. The firm operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The firm's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The firm sells its products in domestic and overseas markets such as Europe and the United States.

Contact

INCHEON
Incheon
23, Academy-ro, Yeonsu-gu
+8216618722
https://www.celltrion.com/

IPO

2005-07-19

Employees

-

Officers

CEO & Internal Director
Mr. Woo-Sung Kee
Co-CEO & Inside Co-Chairman of the Board
Jin-seok Seo
Founder
Mr. Stephen Yeum
Director of Finance
Mr. Min-Cheol Shin
Director of Legal Affairs
Mr. Ji-Hoon Choi

See Also

Discover More
What is the Intrinsic Value of one Celltrion Inc stock?

The intrinsic value of one Celltrion Inc stock under the Base Case scenario is 154 988.39 KRW.

Is Celltrion Inc stock undervalued or overvalued?

Compared to the current market price of 183 400 KRW, Celltrion Inc is Overvalued by 15%.